Cathie Wood-Led Ark Invest Sells PLTR, GOOG, SHOP Stocks — But Loads Up On PACB, FRNM And Other Biotech Firms
Cathie Wood's Ark Invest sold shares of Palantir (PLTR), Alphabet (GOOG), Shopify (SHOP), and others, while adding positions in biotech firms like Pacific Biosciences (PACB), Scribe Therapeutics (SCTX), and Freenome (FRNM). The trades occurred across several ARK ETFs, including ARK Innovation and ARK Genomic Revolution.
How this was made
The 30-second read
Why it matters
The disclosed trades provide fresh data on fund sentiment toward several tech and biotech names, offering short‑term trading cues.
Market read
Ark’s reallocation signals a shift from high‑growth tech to biotech, potentially influencing short‑term price action in the listed stocks.
What to watch
Ark’s trades could be part of a longer‑term portfolio rebalancing rather than a signal about each company’s near‑term outlook.
Background
Ark Invest, led by Cathie Wood, routinely adjusts its actively managed ETFs, and this article reports its latest portfolio changes on a specific trading day.
Ticker impact
Ark sold 15,302 shares of Palantir in ARKK and 9,240 shares in ARKW, indicating a reduction in exposure.
likely pressure as the market prices in the sell-off
Ark's divestiture signals reduced confidence; similar moves have historically prompted short‑term dips.
Ark sold 65,812 shares of Alphabet (GOOG) across ARKK and ARKW, trimming its stake in the tech giant.
likely pressure as the market absorbs the sell news
Alphabet is a large cap; a sell by Ark is news but limited in scale relative to float.
Ark sold 17,740 shares of Shopify (SHOP) in ARKK, further decreasing its holding.
likely pressure as the market reacts to the sell
Shopify’s price is sensitive to fund flows; Ark’s exit is a bearish signal.
Ark sold 9,215 shares of Cloudflare (NET) in ARKK and additional shares in ARKW, cutting exposure.
likely pressure as the market prices in the sell
Cloudflare is a growth stock; fund exits can trigger short‑term sell pressure.
Ark sold shares of CrowdStrike (CRWD) in ARKW as part of a broader tech reduction.
likely pressure as the market absorbs the sell
CRWD is a high‑growth security firm; fund exits are viewed negatively.
Ark bought 68,266 shares of Pacific Biosciences (PACB) in ARKG, adding exposure to the biotech ETF.
likely support as the market prices in the buy
Ark’s biotech focus often moves small‑cap stocks; new buying can lift price.
Ark added 22,479 shares of Scribe Therapeutics (SCTX) to ARKG, expanding its biotech holdings.
likely support as the market reacts to the purchase
Small‑cap biotech often rallies on institutional buying.
Ark purchased 169,498 shares of Freenome (FRNM) in ARKG, significantly increasing its stake.
likely support as the market prices in the large buy
Freenome is a micro‑cap; large fund purchases can trigger notable price moves.
Market effects
Tech sector may see slight short‑term weakness from Ark’s tech sell‑off; biotech sector could benefit from Ark’s focused buying.
U.S. equity markets may experience modest volatility in the affected stocks.
Limited to U.S. listed equities; no broader macro impact.
Counterpoint
Some investors may view the tech sells as a buying opportunity if they believe the fundamentals remain strong.
Key entities
- personCathie Wood
Founder of Ark Invest, leading the fund’s strategic decisions.
- fundArk Innovation ETF (ARKK)
Ark’s flagship actively managed ETF, which reduced holdings in several tech stocks.
- fundArk Genomic Revolution ETF (ARKG)
Ark’s biotech‑focused ETF, which added positions in several small‑cap biotech firms.
